+34 679 490 537info@nanbiosis.com

Posts Taged nanomol

Validation of a drug for foot ulcers in collaboration with Cuba

Nanomol, (Unit 6 of NANBIOSIS) has announced in Cuba that the process of clinical validation of a new drug developed and patented in collaboration with Center of Genetic Engineering and Biotechnology of Cuba, integrated in BioCubaFarma, has been initiated. The new drug is designed to improve the healing of foot ulcer in diabetics and could be on the market in five years.

The collaboration of the Center for Genetic Engineering and Biotechnology of Cuba with Nanomol, coordinating group of Unit 6 of NANBIOSIS, began in 2010. Cuban researchers had developed an effective product in wound healing in diabetics but the product had to be Administered with injections in the affected area. Nanomol obtained a nanoformulation with which it is possible to integrate the protein in a nanovesícula, so that the active principle of its degradation is protected once it is applied in the wound and, in addition, is obtained that the protein is released of suitable form. The results of the work have resulted in a patent and currently the process of validation and scaling of pharmaceutical production is being carried out to bring the product to market.

U6 of NANBIOSIS has played an important role in the development of this potential nanomedicine since it enabled a detailed characterization of several physico-chemical properties of the multifunctional nanovesicles used to construct it.

Validation of a drug for foot ulcers in collaboration with Cuba
Read More

Synergies produced in NANBIOSIS multiply the value of its services and allow its users to have results with faster and superior reliability due to proven experience of the scientists and technicians involved, says Jaume Veciana, Scientific Director of NANBIOSIS, in an interview at July 2016 CIBER-BBN Bulletin.

In this interview, Jaume Veciana assesses the functioning of this Singular Scientific-Technical Infrastructure and its contribution to research and anticipates some of the guidelines of the NANBIOSIS Strategic Plan 2017-2020, which includes a clear commitment to internationalization.

“The scientific-technical capabilities available at NANBIOSIS must be exploited without limitation to our country. Therefore we are clear that we must promote the activity of NANBIOSIS both academic and industrial sector in the European Union and other countries, either directly or in association with other similar organizations actions. Some such initiatives have already started but we believe it should be given further boost to internationalization. As an example we can mention the participation in the European project INFRAIA that aims to integrate regional and national research infrastructures existing in Europe under the Horizon 2020”

Professor Veciana also talks about NANOMOL, the research group coordinator of Unit 6 of NANBIOSIS, and the main applications of their findings in the fields of nanomedicine and biomaterials.

To know more

Synergies produced in NANBIOSIS multiply the value of its services and allow its users to have results with faster and superior reliability due to proven experience of the scientists and technicians involved, says Jaume Veciana, Scientific Director of NANBIOSIS, in an interview at July 2016 CIBER-BBN Bulletin.
Read More
Nanbiosis